273 related articles for article (PubMed ID: 38058096)
1. Recent Progress and Challenges in Clinical Translation of Nanomedicines in Diagnosis and Treatment of Lung Cancer.
Yadav B; Chauhan M; Singh RP; Sonali ; Shekhar S
Curr Drug Targets; 2024; 25(1):12-24. PubMed ID: 38058096
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for Treatment of Lung Cancer.
Hussain S
Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
[TBL] [Abstract][Full Text] [Related]
3. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
Jiang Y; Jiang Z; Wang M; Ma L
Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine Tumor Targeting.
Lammers T
Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of nanomedicines in lung cancer treatment.
Norouzi M; Hardy P
Acta Biomater; 2021 Feb; 121():134-142. PubMed ID: 33301981
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. Loco-regional administration of nanomedicines for the treatment of lung cancer.
Garrastazu Pereira G; Lawson AJ; Buttini F; Sonvico F
Drug Deliv; 2016 Oct; 23(8):2881-2896. PubMed ID: 26585837
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment.
Li J; Zhu L; Kwok HF
Drug Resist Updat; 2023 Jan; 66():100904. PubMed ID: 36462375
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
Kwon S; Ko H; You DG; Kataoka K; Park JH
Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines in Diagnosis and Treatment of Cancer: An Update.
Haider N; Fatima S; Taha M; Rizwanullah M; Firdous J; Ahmad R; Mazhar F; Khan MA
Curr Pharm Des; 2020; 26(11):1216-1231. PubMed ID: 32188379
[TBL] [Abstract][Full Text] [Related]
13. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
14. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
[TBL] [Abstract][Full Text] [Related]
15. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
16. Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review.
Fathi-Karkan S; Arshad R; Rahdar A; Ramezani A; Behzadmehr R; Ghotekar S; Pandey S
Eur J Med Chem; 2023 Nov; 259():115676. PubMed ID: 37499287
[TBL] [Abstract][Full Text] [Related]
17. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
18. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
20. Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.
Maurya S; Srivastava R; Arfin S; Hawthorne S; Jha NK; Agrawal K; Raj S; Rathi B; Kumar A; Raj R; Agrawal S; Paiva-Santos AC; Malik AA; Dua K; Rana R; Ojha S; Jha SK; Sharma A; Kumar D; El-Zahaby SA; Nagar A
Nanomedicine (Lond); 2022 Dec; 17(30):2245-2264. PubMed ID: 36975758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
